Announcements
- Axogen, Inc Reports First Quarter 2024 Financial Results
- Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
- Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
- Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
- Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
- Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
- Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
- Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
- Axogen Announces Promotions on Research and Development Team
More ▼
Key statistics
As of last trade, AxoGen Inc (0HKD:LSE) traded at 5.57, 59.14% above the 52 week low of 3.50 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 5.57 |
Average volume | 190.75 |
---|---|
Shares outstanding | 43.70m |
Free float | 40.61m |
P/E (TTM) | -- |
Market cap | 247.80m USD |
EPS (TTM) | -0.4943 USD |
Data delayed at least 20 minutes, as of May 06 2024 18:08 BST.
More ▼